Discovering a Common Goal,
Discovering a Cure

CONTACT  |  DONATE  |  E-NEWSLETTER  | 
  
DRUG NEWS

Research News
Drug News
Conference News
< Home



$100 Million Public-Private Venture Fund to Focus on Dementia Research
March 25, 2015

The difficult funding climate of NIH budget cuts and pharmaceutical companies withdrawing from early stage research and development in the neurosciences creates a need for creative funding solutions to continue to fuel the drug development...

Cal State Team Developing Affordable Brain-Computer Interface Communication Device for ALS Patients
March 25, 2015
A team of researchers from California State University, Fullerton, has received funding from the Disability Communications Fund to develop a low-cost, brain-computer interface-based communication device for ALS patients within a year. The team,...
Treeway’s ALS Drug Candidate TW001 Granted Orphan Drug Designation
March 25, 2015
The Dutch biotechnology company Treeway, founded by the ALS patients and entrepreneurs Bernard Muller and Robbert Jan Stuit (see Jan 2015 news story) has...
AB Science Obtains Orphan Drug Designation for Masitinib
March 20, 2015

AB Science has announced that its ALS drug candidate masitinib, which is in Phase III clinical trials for ALS, has been granted orphan drug designation by the FDA. Masitinib, an inhibitor of c-kit...

Neuralstem Announces Promising Phase II Clinical Trial Results of NSI-566 in ALS
March 12, 2015
Neuralstem has announced top line results of its Phase II clinical trial of NSI-566 in ALS (see Nov 2014 news story). The trial enrolled 15 ALS patients...




The ALS Forum was developed by Prize4Life, Inc.
 
© 2015 Prize4Life, Inc.
Identified content provided through
a partnership with the Alzforum